Fig. 2From: Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancerClonogenic analysis of four CRC cell lines exposed to TAK-960. a HCT116, b WIDR, c DLD1, d COLO678 were plated in 6 well plates and exposed to increasing concentrations of TAK-960 for 72 h or mock treated control. Drug was removed and replaced with media to allow for regrowth of clones. Cells were stained with crystal violet, photographed and quantitated using ImageJ software using the Colony Area Plugin. *p < 0.05, **p < 0.01 by paired t-test. N≥3Back to article page